Evidence map›Paper›PMID 38223832›Full record

ArticleQatar medical journal2023

Dilemma of Thrombolysis in a patient with high-risk Pulmonary Embolism with severe Thrombocytopenia: A case report.

Phool Iqbal, Mhd Baraa Habib, Ahmed Hatim, Mohammed Alkhatib, Muhammad Abu Bakar, Sunil Hassan Koya, Awni Alshurafa, Habib Ur Rehman

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Qatar medical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Phool IqbalDepartment of Internal Medicine, New York Medical College/Metropolitan Hospital Center, New York, USA.
Mhd Baraa HabibDepartment of Internal Medicine, Hamad Medical Corporation, Qatar Email: MAbubakar@hamad.qa.
Ahmed HatimDepartment of Internal Medicine, Hamad Medical Corporation, Qatar Email: MAbubakar@hamad.qa.
Mohammed AlkhatibDepartment of Internal Medicine, Hamad Medical Corporation, Qatar Email: MAbubakar@hamad.qa.
Muhammad Abu BakarDepartment of Internal Medicine, Hamad Medical Corporation, Qatar Email: MAbubakar@hamad.qa.
Sunil Hassan KoyaDepartment of Medical ICU, Hamad Medical Corporation, Qatar.
Awni AlshurafaDepartment of Hematology, Hamad Medical Corporation, Qatar.
Habib Ur RehmanDepartment of Medical ICU, Hamad Medical Corporation, Qatar.
Hamad Medical Corporation · QANew York Medical College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundManaging a high-risk pulmonary embolism (PE) in a critically ill patient with severe thrombocytopenia can present a challenging dilemma. There is a high risk of fatal bleeding due to anticoagulation in high-risk PE with thrombocytopenia; therefore, risks and benefits are balanced while dealing with such a critical scenario. CASE REPORT: We present a case of a female patient with thrombocytopenia who was admitted for management of lymphoma. Her hospital course was complicated by high-risk PE, leading to acute respiratory failure and hypotension, necessitating urgent transfer to the medical intensive care unit. She was intubated and placed on mechanical ventilation. Multiple cardiac arrests occurred due to compromised cardiac output from a severely dilated right ventricle on bedside transthoracic echocardiography. As a last resort to save her life in this critical state and severe thrombocytopenia, she was given a half bolus dose of the recommended drug, i.e., 50mg IV of Alteplase. Subsequently, she stabilized and was extubated without any further complications. DISCUSSION: High-risk PE needs prompt management with anticoagulation to avoid fatal outcomes. However, on the other hand, anticoagulation carries a high risk of bleeding, especially in patients with thrombocytopenia. These challenges prompt a modern perspective in situations where clear guidelines are absent.

conclusionWe aim to discuss our contemporary clinical practice in managing such a complex case and highlight the need for further studies.

Indexed as

high-risk PElymphomasevere thrombocytopeniathrombolysis

Identifiers

PMID38223832
PMCPMC10787518
OpenAlexW4390652909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.